Richard Frank, MD
Hematology & Oncology · Norwalk, CTNPI 1174515803
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.3%), speaking fees and education — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Pfizer at 55.2% of the total. Reporting peaked in 2019 at $3,000 and has fallen 81.0% since, to $569 in 2025.
Across 137 payments — averaging $37.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- Bristol Myers Squibb$319
- Novartis$318
- Array Biopharma Inc$248
- AbbVie$246
- Merck$243
- plus $946 from 21 others
Across 286 payments — averaging $11,390 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.5M
- Pfizer$1.5M
- EMD Serono, Inc.$112K
- Morphosys AG$49K
- Janssen Research & Development, LLC$46K
- Bristol Myers Squibb$22K
- plus $61K from 7 others
What the payments were for
- Speaking & faculty fees$2,54049%
- Food & beverage$2,60250%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 22 | $2,854 |
| Bristol Myers Squibb | 19 | $319 |
| Novartis | 13 | $318 |
| Array Biopharma Inc | 11 | $248 |
| AbbVie | 11 | $246 |
| Merck | 16 | $243 |
| Gilead | 8 | $192 |
| Johnson & Johnson | 4 | $82 |
| GSK | 3 | $72 |
| Genentech USA, Inc. | 3 | $61 |
| Sanofi | 3 | $58 |
| Jazz Pharmaceuticals Inc. | 3 | $53 |
| Lilly USA, LLC | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 2 | $46 |
| AstraZeneca | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Mirati Therapeutics, Inc. | 1 | $35 |
| Amgen | 2 | $32 |
| Astellas Pharma US Inc | 1 | $30 |
| ADC Therapeutics America, Inc. | 1 | $28 |
| Eisai Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Legend Biotech USA Inc. | 1 | $17 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Pharmaessentia USA Corporation | 1 | $14 |
| Boehringer Ingelheim | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IBRANCE$2,540
How this compares
$5,174 in reported general payments places this provider in the 65th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JaypircaPirtobrutinib | 36 | $800,662 |
| XtandiEnzalutamide | 11 | $159,457 |
| Abiraterone Acetate | 42 | $68,459 |
| OrgovyxRelugolix | 12 | $32,264 |
| CreonLipase/Protease/Amylase | 20 | $29,116 |
| ZenpepLipase/Protease/Amylase | 14 | $13,904 |
| EliquisApixaban | 12 | $9,280 |
| Clonidine | 13 | $1,875 |
| Prednisone | 74 | $771 |
| Colestipol Hcl | 12 | $597 |
| Acyclovir | 31 | $415 |
| Tamsulosin Hcl | 21 | $377 |
| Dexamethasone | 13 | $295 |
| Duloxetine Hcl | 14 | $261 |
| Ondansetron OdtOndansetron | 14 | $215 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCJaypirca, Olanzapine | $50 | $800,85451 claims |
| Astellas Pharma US IncXtandi | $30 | $159,45711 claims |
| AbbVieCreon | $246 | $29,11620 claims |
| PfizerEliquis | $2,854 | $9,28012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 163 hematology & oncology providers in Connecticut.
Other hematology & oncology in Norwalk
- Richard ZelkowitzNorwalk$54K
- Amer ZeidanNew Haven$807K
- Biree AndemariamFarmington$646K
- Paul WeinsteinStamford$288K
- Walid ShaibNew Haven$217K
- Madhavi GorusuHartford$207K
- Dinesh KapurNorwich$201K
- Scott HuntingtonNew Haven$163K
- Nataliya UbohaNew Haven$124K
- Michael CecchiniNew Haven$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.